BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#300 of 347

Jason Kolbert

D. Boral Capital · Equity Research Analyst
ProvisionalRating since 2024No new ratings since Jun 2025

Analyst rating accuracy & track record

Jason Kolbert is an equity research analyst at D. Boral Capital. Bullish Whales has scored 166 of their stock calls across 34 companies. Their picks beat their sector 21% of the time over the next 12 months, and their price targets were reached 10% of the time within a year.

Win % vs sector
21%
PT Hit % (12mo)
10%
Avg sector-excess
−22.1%
Scored calls
166
Tickers
34
Tier
Provisional

Track record

Bullish Whales has scored 166 of Jason Kolbert's stock calls across 34 companies, dating back to 2024. Their rated stocks beat their own sector 21% of the time over the next 12 months. On a typical call, a Kolbert pick returned −22.1% more than its sector over the following year.

Of the scored calls, 166 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ANIXAnixa Biosciences Inc
Buy$10.00Jun 2025−45.8%Miss
CTXRCitius Pharmaceuticals Inc
Buy$6.00Jun 2025−59.9%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$27.00Jun 2025−112.7%Miss
NNOXNano X Imaging Ltd
Buy$10.00Jun 2025−82.8%Miss
ARTLArtelo Biosciences Inc
Buy$6.00Jun 2025−109.1%Miss
IMUXImmunic Inc
Buy$10.00Jun 2025+46.2%Miss
QNCXQuince Therapeutics, Inc.
Buy$4.00Jun 2025−107.0%Hit
RVPHReviva Pharmaceuticals Holdings Inc.
Buy$3.00Jun 2025−109.0%Miss
ESLAEstrella Immunopharma Inc.
Buy$16.00Jun 2025−7.6%Miss
TRVITrevi Therapeutics Inc
Buy$21.00Jun 2025+114.9%Miss
CLGNCollplant Biotechnologies Ltd
Buy$12.00May 2025−95.8%Miss
ANIXAnixa Biosciences Inc
Buy$10.00May 2025−9.6%Miss
IMUXImmunic Inc
Buy$10.00May 2025+112.0%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$27.00May 2025−115.0%Miss
ESLAEstrella Immunopharma Inc.
Buy$16.00May 2025−6.8%Miss
CLGNCollplant Biotechnologies Ltd
Buy$12.00May 2025−107.1%Miss
NNOXNano X Imaging Ltd
Buy$10.00May 2025−76.2%Miss
NNOXNano X Imaging Ltd
Buy$10.00May 2025−76.2%Miss
NNOXNano X Imaging Ltd
Buy$10.00May 2025−76.2%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$27.00May 2025−126.1%Miss
RVPHReviva Pharmaceuticals Holdings Inc.
Buy$3.00May 2025−111.8%Miss
BMEABiomea Fusion Inc
Buy$16.00May 2025−22.2%Miss
CTSOCytosorbents Crp
Buy$10.00May 2025−55.6%Miss
FBLGFibroBiologics, Inc. Common Stock
Buy$16.00May 2025−105.3%Miss
CRVOCervoMed Inc.
Buy$10.00May 2025−71.3%Hit
OMEROmeros Corporation
Buy$36.00May 2025+249.9%Miss
NRSNNeurosense Therapeutics Ltd
Buy$14.00May 2025−46.5%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$27.00May 2025−121.5%Miss
URGNUroGen Pharma Ltd
Buy$25.00May 2025+181.3%Hit
CNTXContext Therapeutics Inc
Buy$9.00May 2025+194.7%Miss
URGNUroGen Pharma Ltd
Buy$25.00May 2025+173.2%Hit
OMEROmeros Corporation
Buy$36.00May 2025+122.2%Miss
BMEABiomea Fusion Inc
Buy$16.00May 2025−15.2%Miss
CRMDCorMedix Inc
Buy$15.00May 2025−40.4%Hit
CTSOCytosorbents Crp
Buy$10.00May 2025−38.3%Miss
GOVXGeoVax Labs Inc
Buy$9.00May 2025−101.6%Miss
LUNGPulmonx Corp
Buy$17.00May 2025−70.8%Miss
IMUXImmunic Inc
Buy$17.00Apr 2025−26.5%Miss
VNRXVolitionrx Ltd
Buy$5.00Apr 2025−103.3%Miss
CNTXContext Therapeutics Inc
Buy$9.00Apr 2025+166.4%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$14.00Apr 2025−122.4%Miss
CODXCo-Diagnostics, Inc. Common Stock
Buy$10.00Apr 2025−89.9%Miss
CMPXCompass Therapeutics Inc.
Buy$32.00Apr 2025−5.1%Miss
URGNUroGen Pharma Ltd
Buy$25.00Apr 2025+119.0%Hit
ARTLArtelo Biosciences Inc
Buy$6.00Apr 2025−85.5%Miss
CEROCERo Therapeutics Holdings, Inc. Common Stock
Buy$11.00Apr 2025−105.2%Miss
RVPHReviva Pharmaceuticals Holdings Inc.
Buy$8.00Apr 2025−101.0%Miss
CEROCERo Therapeutics Holdings, Inc. Common Stock
Buy$11.00Apr 2025−108.2%Miss
CEROCERo Therapeutics Holdings, Inc. Common Stock
Buy$11.00Apr 2025−109.6%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$14.00Apr 2025−126.4%Miss
Go to

Jason Kolbert: analyst track record FAQ

Is Jason Kolbert a good stock analyst?

Yes, by track record. Jason Kolbert ranks number 300 of 347 of the analysts Bullish Whales scores, with a BW Score of 0 out of 100. Past results do not guarantee future ones.

What is Jason Kolbert's win rate?

Jason Kolbert's win rate is 21%. Across 166 scored calls, their rated stocks beat their sector 21% of the time over the next 12 months. On a typical call they returned −22.1% more than the sector.

What stocks and sectors does Jason Kolbert cover?

Jason Kolbert covers 34 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Jason Kolbert's price targets accurate?

Jason Kolbert's price targets are reached within 12 months 10% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jason Kolbert's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jason Kolbert rank among Wall Street analysts?

Jason Kolbert ranks number 300 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30